1. Home
  2. DTF vs ICCC Comparison

DTF vs ICCC Comparison

Compare DTF & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DTF Tax-Free Income 2028 Term Fund Inc.

DTF

DTF Tax-Free Income 2028 Term Fund Inc.

HOLD

Current Price

$11.35

Market Cap

80.0M

Sector

Finance

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$10.13

Market Cap

75.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTF
ICCC
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.0M
75.8M
IPO Year
1995
1995

Fundamental Metrics

Financial Performance
Metric
DTF
ICCC
Price
$11.35
$10.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.1K
28.0K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
N/A
0.21
Revenue
N/A
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
51.64
52 Week Low
$11.14
$4.52
52 Week High
$11.60
$10.25

Technical Indicators

Market Signals
Indicator
DTF
ICCC
Relative Strength Index (RSI) 41.57 73.69
Support Level $11.26 $5.85
Resistance Level $11.48 N/A
Average True Range (ATR) 0.07 0.50
MACD -0.01 0.12
Stochastic Oscillator 21.10 97.37

Price Performance

Historical Comparison
DTF
ICCC

About DTF DTF Tax-Free Income 2028 Term Fund Inc.

DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: